Rocuronium
- Atc Codes:M03AC09
- CAS Codes:119302-91-9
- PHARMGKB ID:119302-91-9
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Esmeron, Rocuroniumbromid; Belgium: Esmeron, Rocuronium; Bulgaria: Esmeron; Cyprus: Esmeron; Czech Republic: Esmeron, Rocuronium; Denmark: Esmeron; Estonia: Esmeron; Finland: Esmeron; France: Esmeron; Germany: Esmeron, Rocuroniumbromid; Greece: Esmeron; Hungary: Esmeron; Ireland: Esmeron, Rocuronium; Italy: Esmeron, Rocuronio; Latvia: Esmeron; Lithuania: Esmeron; Malta: Esmeron; Netherlands: Esmeron, Rocuroniumbromide; Poland: Esmeron, Rocuronium; Portugal: Esmeron; Romania: Esmeron, Rocuronium; Slovakia: Esmeron, Rocuronium; Slovenia: Esmeron; Spain: Esmeron, Rocuronio; Sweden: Esmeron, Rocuronium; UK: Esmeron.
North America
Canada: Rocuronium, Zemuron; USA: Rocuronium, Zemuron.
Latin America
Brazil: Esmeron; Mexico: Esmeron.
Asia
Japan: Eslax.
Drug combinations
Chemistry
Rocuronium Bromide: C~32~H~53~BrN~2~O~4~. Mw: 609.68. (1) Pyrrolidinium, 1-[(2β,3α,5α,16β,17β)-17-(acetyloxy)-3-hydroxy-2-(4-morpholinyl)androstan-16-yl]-1-(2-propenyl)-, bromide; (2) 1-Allyl-1-(3α,17β-dihydroxy-2β-morpholino-5α-androstan-16β-yl)pyrrolidinium bromide, 17-acetate. CAS-119302-91-9 (1993).
Pharmacologic Category
Neuromuscular-Blocking Agents, Nondepolarizing. (ATC-Code: M03AC09).
Mechanism of action
Blocks acetylcholine from binding to receptors on motor endplate, inhibiting depolarization.
Therapeutic use
Adjunct to general anesthesia to facilitate endotracheal intubation and to relax skeletal muscles during surgery. To facilitate mechanical ventilation in intensive care unit.
Pregnancy and lactiation implications
Crosses placenta. Umbilical venous plasma levels are 18% of maternal concentration. Use not recommended for rapid sequence induction during cesarean section. Excretion in breast milk unknown (use caution).
Unlabeled use
Contraindications
Hypersensitivity to rocuronium or any component of the formulation.
Warnings and precautions
Cross-sensitivity with other neuromuscular-blocking agents may occur (use extreme caution in previous anaphylactic reactions). Resistance may occur in burn patients (>30% of body) for period of 5-70 days postinjury. Use with caution in cardiovascular disease (onset of action may be delayed and duration of action may be prolonged). Alkalosis, hypercalcemia, demyelinating lesions, peripheral neuropathies, denervation, infection, muscle trauma, and diabetes mellitus may result in antagonism of neuromuscular blockade. Electrolyte abnormalities, severe hyponatremia, severe hypocalcemia, severe hypokalemia, hypermagnesemia, neuromuscular diseases, acidosis, acute intermittent porphyria, Eaton-Lambert syndrome, myasthenia gravis, renal failure, and hepatic failure may result in potentiation of neuromuscular blockade. Use with caution in hepatic impairment, in pulmonary hypertension (use may increase pulmonary vascular resistance), and in respiratory disease. Resistance may occur in immobilized patients.